Economic and societal dimensions of nanotechnology-enabled drug delivery

Bibliography

• Parandian A, Rip A, Te Kulve H. Dual dynamics of promises, and waiting games around nanotechnologies. Technol Anal Strategic Manag 2012;24(6):565-82
   Web of Science ®Google Scholar
• Robinson DKR. Co-evolutionary scenarios: an application to prospecting futures of the responsible development of nanotechnology. Technol Forecasting Soc Change 2009;76(9):1222-39
   Web of Science ®Google Scholar
• Rip A, Te Kulve H. Constructive technology assessment and socio-technical scenarios. In: Fisher E, Selin C, Wetmore JM, editors. The yearbook of nanotechnology in society. Volume 1: Presenting Futures. Springer; 2008. p. 49-70
   Google Scholar
• Fenn J, Raskino M. Mastering the hype cycle: how to choose the right innovation at the right time. Harvard Business Press; Bosten, MA; 2008
   Google Scholar
• FORMAKIN. Foresight as a tool for the management of knowledge flows and innovation. Final report of an EU-funded project. 2001. Available from: http://www.york.ac.uk/media/satsu/documents-papers/Brown-Rappert-2001-formakin.PDF [Cited 1 August 2012]
   Google Scholar
• ETP Nanomedicine. Joint European Commission/ ETP Nanomedicine Expert Report 2009: Roadmaps in Nanomedicine Towards 2020; 2009 October 2009
   Google Scholar
• ETP Nanomedicine. Strategic research agenda for nanomedicine. Office for Official Publications of the European Communities, Luxembourg; 2006
   Google Scholar
• ETP Nanomedicine. Vision paper and basis for a strategic research agenda for nanomedicine. Office for Official Publications of the European Communities, Luxembourg; 2005
   Google Scholar
• Krupp F, Holliday C. Let's get nanotech right. Wall Street J 2005;B2
   Google Scholar
• Nordmann A, Rip A. Mind the gap revisited. Nat Nanotechnol 2009;4:273-4
   PubMed Web of Science ®Google Scholar
• Deuten JJ, Rip A, Jelsma J. Societal embedding and product creation management. Technol Anal Stratgic Manag 1997;9(2):131-48
   Web of Science ®Google Scholar
• Fisch A, Tiemessen H, Riebesehl B. Therapeutic nanomedicine: a critical review from the pharmaceutical industry perspective. Swiss biotech roundtable in drug delivery. The Swiss Re Centre for Global Dialogue, Rüschlikon; 2012
   Google Scholar
• Wei A, Mehtala JG, Patri AK. Challenges and opportunities in the advancement of nanomedicines. J Control Release 2012;164(2):236-46
   PubMed Web of Science ®Google Scholar
• Keun Kown I, Cheon Lee S, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012;164(2):108-14
   PubMed Web of Science ®Google Scholar
• DeVille KA. Law, regulation and the medical use of nanotechnology. In: Jotterand B, editor. Emerging conceptual, ethical and policy issues in bionanotechnology. Science + Business Media, Springer; 2008. p. 181-200
   Google Scholar
• Boyd BJ. Past and future evolution in colloidal drug delivery systems. Expert Opin Drug Deliv 2008;5(1):69-85
   PubMed Web of Science ®Google Scholar
• Hoffman AS. The origins and evolution of "controlled" drug delivery systems. J Control Release 2008;132:153-63
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticles - a historical perspective. Int J Pharm 2007;331:1-10
   PubMed Web of Science ®Google Scholar
• Park K. Nanotechnology: what it can do for drug delivery. J Control Release 2007;120:1-3
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23(7):1417-50
   PubMed Web of Science ®Google Scholar
• Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BYS, Rutka JT, Chan WCW. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 2007;4(6):621-33
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005;1:193-212
   PubMed Web of Science ®Google Scholar
• Marcato PD, Durán N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008;8(5):1-14
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Jain TK, Reddy MK, Labhasetwar VD. Nano-sized carriers for drug delivery. In: Shoseyov O, Levy I, editors. Nanobiotechnology: bioinspired devices and materials of the future. Humana Press; Totowa, New Jersey; 2008
   Google Scholar
• Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8:147-66
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006;24(10):1211-17
   PubMed Web of Science ®Google Scholar
• Möschwitzer J, Müller RH. Nanocrystal formulations for improved delivery of poorly soluble drugs. In: Hunter RJ, Preedy VR, editors. Nanomedicine in health and disease. Science Publishers; St. Helier, United Kingdom; 2011. p. 79-99
   Google Scholar
• Boisseau P, Loubaton B. Nanomedicine, nanotechnology in medicine. C R Phys 2011;12(7):620-36
   Web of Science ®Google Scholar
• Cientifica. Market opportunities in nanotechnology drug delivery. 2012. Available from: http://www.cientifica.com/wp-content/uploads/downloads/2012/04/NDD-White-Paper-Jan-2012.pdf [cited 1 August 2012]
   Google Scholar
• Cientifica. Nanotechnology for drug delivery: 2011-2021. 2012. Available from: http://www.cientifica.com/research/market-reports/nanotechnology-for-drug-delivery-2012/ [Cited 2 August 2012]
   Google Scholar
• Bosselmann S, Williams RO III. Has nanotechnology led to improved therapeutic outcomes? Drug Dev Ind Pharm 2012;38(2):158-70
   PubMed Web of Science ®Google Scholar
• Couvreur P. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev 2012
   Web of Science ®Google Scholar
• Adams DJ. The valley of death in anticancer drug development: a reassessment. Trends Pharmacol Sci 2012;33(4):173-80
   PubMed Web of Science ®Google Scholar
• Breimer DD. Future challenges for drug delivery. J Control Release 1999;62:3-6
   PubMed Web of Science ®Google Scholar
• Te Kulve H. Anticipatory Interventions and the Co-evolution of Nanotechnology and Society. PhD thesis. University of Twente, Enschede, The Netherlands; 2011
   Google Scholar
• Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010;141:265-76
   PubMed Web of Science ®Google Scholar
• Keller T. Nanotechnology: cutting through the hype - a realistic business case for Pharma. Investing in Medical Nanotechnologies II, London; 2007
   Google Scholar
• Wagner V, Hüsing B, Gaisser S, Bock A-K. Nanomedicine: drivers for development and possible impacts. Institute for Prospective Technology Studies, Seville; 2006
   Google Scholar
• Papaluca Amati M. Guidance in the medical area. 2nd Annual Nanotechnology Safety for Success Dialogue Workshop, Brussels; 2008
   Google Scholar
• Committee For Medicinal Products for Human Use. Reflection paper on nanotechnology-based medicinal products for human use. European Medicines Agency, Pre-Authorisation Evaluation Of Medicines For Human Use; London: 2006; 29 June 2006. Report No.: EMEA/CHMP/79769/2006
   Google Scholar
• Paradise J, Diliberto GM, Tisdale AW, Kokkoli E. Exploring emerging nanobiotechnology drugs and medical devices. Food Drug Law J 2008;63(2):407-20
   PubMed Web of Science ®Google Scholar
• Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. In: McNeil SE, editor. Characterization of nanoparticles intended for drug delivery. Springer; 2011. p. 17-31
   Google Scholar
• Bawa R. Regulating nanomedicine - can the FDA handle it? Curr Drug Deliv 2011;8(3):227-34
   PubMed Web of Science ®Google Scholar
• Helmus M. The need for rules and regulations. Nat Nanotechnol 2007;2:333-4
   PubMed Web of Science ®Google Scholar
• Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 2009;61:422-7
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008;3(2):133-49
   PubMed Web of Science ®Google Scholar
• Chan VSW. Nanomedicine: an unresolved regulatory issue. Regul Toxicol Pharmacol 2006;46:218-24
   PubMed Web of Science ®Google Scholar
• Zhao J, Castranova V. Toxicology of nanomaterials used in nanomedicine. journal of toxicology and environmental health. Part B 2011;14(8):593-632
   Google Scholar
• Vega-Villa KR, Takemoto JK, Yáñez J, Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 2008;60:929-38
   PubMed Web of Science ®Google Scholar
• Bikiaris D. Nanomedicine in cancer treatment: drug targeting and the safety of the used materials for drug nanoencapsulation. Biochem Pharmacol 2012;1:e122. doi:10.4172/2167-0501.1000e122
   Google Scholar
• Washington C. Medical nanotechnology in the pharmaceutical industry: opportunities and problems. Investing in medical nanotechnologies II, London; 2007
   Google Scholar
• Bawa R. Patents and Nanomedicine. Nanomedicine 2007;2(3):351-74
   PubMed Web of Science ®Google Scholar
• Harris D, Hermann K, Bawa R, Strategies for resolving patent disputes over nanoparticle drug delivery systems. Nanotechnol Law Business 2004;1(4; N.A
   Google Scholar
• Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009;15(2):67-78
   PubMedGoogle Scholar
• Forbes C, Wilby J, Richardson G, A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. Health Technol Assess 2002;6(23).
   Google Scholar
• Johnson S. The era of nanomedicine and nanoethics: has it come, is it Still coming, or will it pass us by? Am J Bioeth 2009;9(10):1-2
   Web of Science ®Google Scholar
• Timmermans J, Zhao Y, Van den Hoven J. Ethics and nanopharmacy: value sensitive design of new drugs. NanoEthics 2011;5(3):269-83
   PubMedGoogle Scholar
• Ebbesen M, Jensen TG. Nanomedicine: techniquese, potentials, and ethical implications. J Biomed Biotechnol 2006;2006:1-11
   Google Scholar
• Resnik DB, Tinkle SS. Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials 2007;28:433-41
   PubMed Web of Science ®Google Scholar
• Bawa R, Johnson S. Emerging issues in nanomedicine and ethics. In: Allhoff F, Lin P, editors. Nanotechnology & society: current and emerging ethical issues. Springer; 2009. p. 207-23
   Google Scholar
• Arnaldi S, Piccinni M. Nanotechnologies and equal access to healthcare. Stud Ethics Law Technol 2009;3(3); ISSN (Online) 1941-6008, DOI: 10.2202/1941-6008.1116
   Google Scholar
• Eaton M, Weltring K-M. ETP Nanomedicine - Opinion Paper. The Impact of Open Innovation on (Nano-) Healthcare R&D in Europe: ETP Nanomedicine; 2010
   Google Scholar
• Eaton MAW. Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry. J Control Release 2012;164(3):370-1
   PubMed Web of Science ®Google Scholar
• Atkinson-Grosjean J. Public science, private interests. Culture and commerce in canada's networks of centres of excellence. University of Toronto Press; Toronto, Buffalo, London; 2012
   Google Scholar
• Butler D. Crossing the valley of death. Nature 2008;453:840-2
   PubMed Web of Science ®Google Scholar
• O'Connell D, Roblin D. Translational research in the pharmaceutical industry: from bench to bedside. Drug Discov Today 2006;11(17/18):833-8
   PubMed Web of Science ®Google Scholar
• Wainwright SP, Williams C, Michael M, From bench to bedside? Biomedical scientists' expectations of stem cell science as a future therapy for diabetes. Soc Sci Med 2006;63:2052-64
   PubMed Web of Science ®Google Scholar
• Enna SJ, Williams M. Defining the role of pharmacology in the emerging world of translational research. Adv Pharmacol 2009;57:1-30
   PubMedGoogle Scholar
• CLINAM. What & Who. 2010. Available from: http://www.clinam.org/what-a-who.html [Cited 1 June 2010]
   Google Scholar
• ESNAM. ESNAM: The Focus on Clinical/Applied Nanomedicine. 2010. Available from: http://www.esnam.org/ [Cited 1 June 2010]
   Google Scholar
• Alliance for Nanohealth. About Nanohealth alliance. 2012. Available from: http://www.nanohealthalliance.org/about-us [Cited 2012 August 7]
   Google Scholar
• Collins M. Next Step: Nanomedicine. 2005. Available from: http://meetingsnet.com/cmepharma/cme/meetings_next_step_nanomedicine [Cited 3 June 2010]
   Google Scholar
• American Society for Nanomedicine. ASNM Purpose, Focus and Vision. 2012. Available from: http://www.amsocnanomed.org/aboutus.php [Cited 7 August 2012]
   Google Scholar
• Alliance for Nanohealth. FDA-ANH Program. 2010. Available from: www.nanohealthalliance.org/fda-anh-program-2 [Cited 31 May 2010]
   Google Scholar